Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Könsgen D[au]:

Search results

Items: 24

1.

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.

Türbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA, Bujard H, Olek A, Olek K, Gellhaus K, Braicu I, Könsgen D, Fryer C, Ravot E, Hellwag A, Westerfeld N, Gruss OJ, Meissner M, Hasan MT, Weber M, Hoffmüller U, Zimmermann S, Loddenkemper C, Mahner S, Babel N, Berns E, Adams R, Zeilinger R, Baron U, Vergote I, Maughan T, Marme F, Dickhaus T, Sehouli J, Olek S.

Epigenetics. 2013 Nov;8(11):1226-35. doi: 10.4161/epi.26334. Epub 2013 Sep 26.

PMID:
24071829
2.

Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis.

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Noske A, Weichert W, Buckendahl AC, Budczies J, Müller BM, Elwali NE, Dietel M, Denkert C.

Histopathology. 2009 May;54(6):657-66. doi: 10.1111/j.1365-2559.2009.03297.x.

PMID:
19438741
3.

A prognostic gene expression index in ovarian cancer - validation across different independent data sets.

Denkert C, Budczies J, Darb-Esfahani S, Györffy B, Sehouli J, Könsgen D, Zeillinger R, Weichert W, Noske A, Buckendahl AC, Müller BM, Dietel M, Lage H.

J Pathol. 2009 Jun;218(2):273-80. doi: 10.1002/path.2547.

PMID:
19294737
4.

Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Weichert W, Noske A, Budczies J, Müller BM, Buckendahl AC, Röske A, Eldin Elwali N, Dietel M, Denkert C.

Mod Pathol. 2009 Apr;22(4):579-88. doi: 10.1038/modpathol.2009.14. Epub 2009 Mar 6.

5.

Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.

Mustea A, Pirvulescu C, Könsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J.

Cytokine. 2008 Apr;42(1):77-84. doi: 10.1016/j.cyto.2008.01.011. Epub 2008 Mar 7.

PMID:
18329282
6.

Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer.

Hefler LA, Mustea A, Könsgen D, Concin N, Tanner B, Strick R, Heinze G, Grimm C, Schuster E, Tempfer C, Reinthaller A, Zeillinger R.

Clin Cancer Res. 2007 Feb 1;13(3):898-901.

7.

Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients.

Oskay-Ozcelik G, Lehmacher W, Könsgen D, Christ H, Kaufmann M, Lichtenegger W, Bamberg M, Wallwiener D, Overkamp F, Diedrich K, von Minckwitz G, Höffken K, Seeber S, Mirz R, Sehouli J.

Ann Oncol. 2007 Mar;18(3):479-84. Epub 2007 Feb 1.

PMID:
17272832
8.

An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66.

9.

Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients.

Ioana Braicu E, Mustea A, Toliat MR, Pirvulescu C, Könsgen D, Sun P, Nürnberg P, Lichtenegger W, Sehouli J.

Gynecol Oncol. 2007 Mar;104(3):680-5. Epub 2006 Dec 1.

PMID:
17141301
10.

Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.

Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Könsgen D, Dietel M, Fiehn O.

Cancer Res. 2006 Nov 15;66(22):10795-804.

11.

An estrogen receptor alpha-dependent regulation of estrogen receptor-related receptor alpha in the proliferation of endometrial carcinoma cells.

Sun PM, Gao M, Wei LH, Mustea A, Wang JL, Könsgen D, Lichtenegger W, Sehouli J.

Int J Gynecol Cancer. 2006;16 Suppl 2:564-8.

PMID:
17010074
12.

Expression of IL-10 in patients with ovarian carcinoma.

Mustea A, Könsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J.

Anticancer Res. 2006 Mar-Apr;26(2C):1715-8.

13.

Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.

Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E.

Neoplasia. 2006 Jan;8(1):38-45.

14.

The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer.

Sun PM, Wei LH, Luo MY, Liu G, Wang JL, Mustea A, Könsgen D, Lichtenegger W, Sehouli J.

Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):249-57. Epub 2006 Mar 7.

PMID:
16519988
15.

Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients.

Gericke B, Raila J, Sehouli J, Haebel S, Könsgen D, Mustea A, Schweigert FJ.

BMC Cancer. 2005 Oct 17;5:133.

16.

[Role of PAI-1 in gynaecological malignancies].

Könsgen D, Mustea A, Lichtenegger W, Sehouli J.

Zentralbl Gynakol. 2005 Jun;127(3):125-31. Review. German.

PMID:
15915389
17.

Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells.

Sun P, Sehouli J, Denkert C, Mustea A, Könsgen D, Koch I, Wei L, Lichtenegger W.

J Mol Med (Berl). 2005 Jun;83(6):457-67. Epub 2005 Mar 16.

PMID:
15770498
18.

[Conventional and experimental prognostic factors in ovarian cancer].

Sehouli J, Mustea A, Könsgen D, Lichtenegger W.

Zentralbl Gynakol. 2004 Oct;126(5):315-22. Review. German.

PMID:
15478050
19.

Prognostic significance of epithelial cells in the blood of patients with gynaecological malignancies.

Sehouli J, Könsgen D, Nimpsch R, Stengel D, Oskay G, Mustea A, Oertel J, Lichtenegger W.

Anticancer Res. 2003 Sep-Oct;23(5b):4133-40.

PMID:
14666614
20.

["IMO"--intraoperative mapping of ovarian cancer].

Sehouli J, Könsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, Lichtenegger W.

Zentralbl Gynakol. 2003 Mar-Apr;125(3-4):129-35. German.

PMID:
12961105
21.

Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.

Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A, Lichtenegger W.

Anticancer Res. 2003 Mar-Apr;23(2A):1115-8.

PMID:
12820357
22.

Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer.

Mustea A, Sehouli J, Könsgen D, Stengel D, Sofroni D, Lichtenegger W.

Anticancer Res. 2003 Mar-Apr;23(2A):1099-102.

PMID:
12820354
23.

Detection of epithelial carcinoma cells in the blood of patients with gynaecological malignancies.

Sehouli J, Könsgen D, Nimpsch R, Oskay G, Stengel D, Oertel J, Lichtenegger W, Mustea A.

Anticancer Res. 2003 Mar-Apr;23(2A):1093-7.

PMID:
12820353
24.

Polymorphism of IL-1 receptor antagonist gene: role in cancer.

Sehouli J, Mustea A, Könsgen D, Katsares I, Lichtenegger W.

Anticancer Res. 2002 Nov-Dec;22(6A):3421-4. Review.

PMID:
12530098

Supplemental Content

Loading ...
Support Center